Introduction
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease, which elicits motor disturbances such as tremors, rigidity, bradykinesia and akinesia (Sian et al., 1999) . Pathological features of PD are characterized by intracellular inclusions, Lewy bodies, and a marked loss of nigrostriatal dopaminergic neurons in the brain (Ehringer and Hornykiewicz, 1960) . Currently, there are several effective medications to treat the symptoms by compensation of decreased dopamine, such as the use of levodopa and dopamine agonists. However, these medications neither protect progressive dopaminergic cell loss per se in PD progression nor improve the problems of dyskinesia and their fluctuating efficacies after long-term use (Marek et al., 2002; Fahn and the Parkinson Study Group, 2005) . Therefore, novel and potential drugs are still needed to protect or ameliorate progressive dopaminergic neuronal degeneration (Koller and Tse, 2004 ).
In the etiology of idiopathic PD, the mechanism of neuronal death is not fully understood. It has been reported that inflammation is up-regulated in brains of PD patients (McGeer et al., 1988; Whitton, 2007) , and parallel changes in microglial activation and corresponding dopaminergic terminal loss are observed in the affected nigrostriatal pathway of early PD (Ouchi et al., 2005) . Despite some controversial findings, the beneficial effects of non-aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) on PD progression have been supported by several epidemiological studies (Chen et al., 2003; Hernan et al., 2006; Ton et al., 2006) , suggesting that antiinflammatory agents may prevent neuronal death in PD. In an experimental PD model, NSAIDs, aspirin, meloxicam, indomethacin and rofecoxib, have displayed neuroprotective effects in vivo (Kurkowska-Jastrzebska et al., 2002; Teismann and Ferger, 2001; Teismann et al., 2003) .
The neuronal protective effect of NSAIDs has been supposedly achieved through the inhibition of cyclooxygenase (COX)-2 that subsequently reduce toxic mediators (such as inflammatory cytokines and oxidants) derived from activated microglia, which have been observed in the affected substantia nigra pars compacta of PD patients (McGeer et al., 1988; Ouchi et al., 2005) . However, up-regulation of COX-2 has been found not only in microglia but also in neurons of substantia nigra pars compacta of PD patients and mice intoxicated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Liberatore et al., 1999; Teismann et al., 2003) . The role of neuronal COX-2 in neuronal death related to PD pathogenesis remains unknown.
The present study investigated whether NSAIDs directly rescued neuronal death via COX-2 inhibition in a neural cell line. The protective effect of NSAIDs on neuronal death induced by 1-methyl-4-phenyl pyridinium (MPP + ), a toxic metabolite of MPTP (Chiba et al., 1984; Cleeter et al., 1992) , was studied using human dopaminergic SH-SY5Y neuroblastoma cells which express COX-2 (Alique et al., 2007) . Furthermore, we identified the signal pathway related with the neuroprotective effect exhibited by a certain NSAID (meloxicam), and proposed possible therapeutic application of meloxicam in PD treatment.
Results

Effects of NSAIDs on cell toxicity induced by MPP + exposure
Treatment with MPP + showed a marked decrease in cell viability and an increase in lactate dehydrogenase (LDH) leakage in SH-SY5Y cells (Fig. 1) 1 ). We further confirmed this neuroprotective effect of meloxicam with the propidium iodide (PI)-stained assay by which dead cells were identified and counted directly using a fluorescence microscope (Fig. 2B ). In addition, meloxicam completely prevented morphological changes in surviving cells after MPP + exposure ( Fig. 2A ). Indomethacin and NS-398 showed limited effectiveness against cell viability, yielding a weak -moderate beneficial effect (only when the effect was assessed by the cell viability both in the presence and absence of MPP + ; Fig. 1A ). The other chemicals, CAY-10404 and ibuprofen, did not attenuate the MPP + toxicity.
Effect of meloxicam on cell toxicity of rotenone, MG-132, tunicamycin or ethacrynic acid
To characterize the neuroprotective effects of meloxicam, we evaluated the effects of meloxicam on toxicities induced by 4 different types of cytotoxic agents (rotenone: a mitochondrial complex I inhibitor; MG-132: a proteasome inhibitor; tunicamycin: an endoplasmic reticulum stress inducer; and ethacrynic acid: a reducing agent of cellular glutathione). Meloxicam elicited significant (p < 0.001) protective effects on cells exposed to MPP + (3 mM) for 48 h (Fig. 3) . However, no favorable effect of meloxicam on cell viability was observed when cells were incubated with rotenone, MG-132, tunicamycin or ethacrynic acid (Fig. 3A) . When cell toxicity was based on LDH leakage, meloxicam prevented cell toxicity induced by 10 µM ethacrynic acid (p < 0.05) without affecting LDH leakage induced by rotenone, MG-132 or tunicamycin (Fig. 3B ).
Involvement of anti-apoptotic intracellular signaling pathway
The involvement of major anti-apoptotic intracellular signaling pathways (such as the MEK/ERK and PI3K/Akt) in the mechanism of meloxicam effect was investigated. Either PD985059 (MEK inhibitor) or LY294002 (PI3K inhibitor) was incubated with MPP + (5 mM) and meloxicam (10 µM) for 24 h before cell toxicity was evaluated based on cell viability and LDH assays. Results with PD98059 (1 and 10 µM) and LY294002 (1 and 10 µM) did not indicate any improvement on MPP + -induced cell damage (Fig. 4) (Fig. 2A) .
Effect of meloxicam on phosphorylation of Akt, ERK, JNK and p38
To confirm the involvement of PI3K/Akt pathway in the mechanism of meloxicam action, phosphorylation of Akt at serine 473 was measured after incubation with MPP + using
Western blot analysis. 
Discussion
In this study, we demonstrated that meloxicam protected neuronal damage from MPP + toxicity in SH-SY5Y cells, although the other NSAIDs tested did not prevent MPP + -induced neuronal death. When assessed by the cell viability test, indomethacin and NS-398 slightly attenuated MPP + -induced toxicity. However, both drugs slightly promoted cell growth in cultured media without MPP + through an unknown mechanism, and did not show any significant protective effect as evaluated by the LDH leakage test.
Thus, these drugs would not indicate neuroprotective activity against MPP + cytotoxicity.
NS-398 and CAY-10404 are more potent and selective COX-2 inhibitors than meloxicam (Habeeb et al., 2000; Warner et al., 1999) . COX-2 protein has been previously shown to be expressed in SH-SY5Y cells (Alique et al., 2007) , and this was confirmed in this study (data not shown). These results imply that the neural protective effect of meloxicam could be mediated by a mechanism different from COX-2 inhibition. Additionally, MPP + toxicity has been shown to develop independently from COX activity in rat mesencephalic primary cultured cells (Carrasco et al., 2005) .
The second interesting finding of this study indicated that meloxicam showed a specific neuroprotective effect against MPP + -induced toxicity without affecting toxicities induced by other types of cytotoxic agents (such as rotenone, MG-132, tunicamycin and ethacrynic acid). This result strongly suggests that meloxicam exerts the neuroprotective effect by acting on a molecule related to the intracellular signaling cascade involved in the onset of MPP + toxicity. Rotenone and MPP + have a toxicological mechanism similar to that of mitochondrial complex I inhibitors, which cause mitochondrial dysfunction to eventually inflict cell death. However, our results suggest that the mechanism of MPP + to induce mitochondrial dysfunction should be different from that of rotenone. Therefore, the site of action involved in the neuronal protection of meloxicam is most likely to be at the upstream signaling cascade prior to the mitochondria in the MPP + -induced neuronal death. The recently established two pro-apoptotic molecules, p38 MAP kinase and c-Jun N-terminal kinase (JNK), are rapidly activated (Cassarino et al., 2000) before the mitochondrial collapse (Fall and Bennett, 1999) when SH-SY5Y cells are exposed to MPP + .
A JNK activation inhibitor, CEP-1347, suppresses MPTP-induced nigral dopaminergic cell death in vivo (Saporito et al., 1999) . Rotenone-induced neuronal death in SH-SY5Y cells is also attenuated by genetic suppression of JNK or p38 pathway (Newhouse et al., 2004 From the above findings, we formulated the following hypothesis ( 
Experimental procedures
Materials
All antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA).
CAY10404, MG-132 and wortmannin were obtained from Cayman Chemical (Ann Arbor, MI, USA) and Calbiochem (San Diego, CA, USA), respectively. MPP + iodide, indomethacin, meloxicam sodium hydrate, tunicamycin, PD98059, and LY294002 were from Sigma (St Louis, MO, USA). All other chemicals (Wako, Osaka, Japan) used in the experiments were either of the highest or analytical grade.
Cell culture and drug treatment
SH-SY5Y human neuroblastoma cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing heat-inactivated fetal bovine serum (FBS, 10%), penicillin (100 U/ml) and streptomycin (100 µg/ml) before being seeded onto a 6-or 96-well plate or a chamber slide at 1.5 x 10 5 cells/cm 2 and cultured in a humidified incubator (95% air and 5% CO 2 ) for 24 h at 37ºC. After rinsing, cells in the plates were treated with a test-agent (dissolved in 0.1% ethanol or dimethyl sulfoxide) for 4 -48 h in the serum-free culture medium containing antibiotics.
Evaluation of cell toxicity
Cell viability was assessed by measuring optical density at 450 nm with a microplate reader (ImmunoMini NJ-2300, System Instruments, Tokyo, Japan) after 2.5-h loading with WST-8 test reagent (Dojindo, Kumamoto, Japan). Cell damage was determined by the LDH leakage into the culture medium from cells using the LDH-cytotoxic test (Wako, Osaka, Japan). LDH leakage was determined by measuring the optical density at 540 nm.
When cells were treated with culture medium containing 1% Tween 20, LDH leakage into the culture medium was designated as 100%.
Cells were stained with PI and Hoechst 33342 after 24-h incubation with tested drugs.
PI is membrane impermeant and generally excluded from viable cells, and is commonly 
DNA fragmentation assay
After 18-h exposure to each drug, treated cells were rinsed with phosphate-buffered saline (PBS, pH 7.4) and lysed with 100 μl of lysis buffer containing 10 mM Tris-HCl (pH 7.4), 10 mM EDTA and 0.5% TritonX-100 for 10 min at 4ºC. The cell lysate was centrifuged at 15,000 x g for 10 min at 4ºC, and the decanted supernatant was treated with RNase A solution (2 µl, 10 mg/ml) and further incubation for 60 min at 37ºC. The mixture was thereafter treated with a 2-µl aliquot of proteinase K solution (> 600 units/ml) before standing for 30 min at 50ºC. The mixture was further treated with concentrated NaCl (5 M) and isopropanol (final concentrations: 0.5 M, 50% respectively), and allowed to stand overnight at -20ºC. The mixture was then centrifuged at 15,000 x g for 20 min at 4ºC, and the supernatant was discarded. The pellet was suspended in 20 µl of 10 mM Tris buffer (pH 7.4) containing 1 mM EDTA. After the DNA concentration was determined by monitoring absorbance at 260 nm, the DNA sample (20 µg) was mixed with bromphenol blue (final concentration: 0.04%) and sucrose (final concentration: 6.7%) and electrophoresed on 1.5 % agarose gel with 90 mM Tris-borate buffer (pH 8.3) containing 2 mM EDTA and 1 µg/ml ethidium bromide. DNA fragmentation was observed under ultraviolet light.
Western blotting
After rinsing with ice-cold PBS (1 ml), cells were sonicated in 100 µl of ice-cold lysis buffer containing 20 mM Tris buffer (pH 7.5), 250 mM NaCl, 1% Triton X-100, 1mM
EDTA, 1mM dithiothreitol, 10 mM NaF, 2 mM sodium orthovanadate and the protease-inhibitor cocktail (EDTA-free complete type; Roche Applied Science, Switzerland). Cellular debris was removed from the lysate by centrifugation (15,000 x g), and the protein content of supernatant was determined using the BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA). After boiling with Laemmli buffer for 5 min, proteins (20 µg) separated by 7.5% SDS-polyacrylamide gel electrophoresis were electrophoretically transferred onto a polyvinylidene fluoride membrane. The membrane was sequentially treated with Block Ace (DS Pharma Biomedical, Osaka, Japan) and incubated overnight at 4ºC with anti-phosphorylated-Akt (1 : 1,000) or anti-Akt (1 : 5,000) from rabbit in 10mM Tris buffer (pH 7.5) containing 0.9% NaCl, 0.05% Tween 20 and 10% methanol (TBST). For the other antibodies for phosphorylated-and total-MAP kinases and full and cleaved caspase-3, the dilution at 1:1,000 in TBST was used except for anti-phosphorylated ERK and β-actin (1 : 2,000). The membrane was washed three times with TBST and probed with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG temperature. The washing procedure was repeated before the membrane was treated with a chemiluminescent reagent (ECLplus, GE Healthcare, Little Chalfont, UK). The proteins were visualized using an LAS3000 image analyzer (FUJIFILM, Tokyo, Japan).
Statistical Analysis
Data were analyzed by one factorial ANOVA followed by the Tukey's multiple comparison test for post-hoc significance testing. The Student's t-test was used for comparison between two groups at any one time. 
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